Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of HSK44459 in IPF
NCT07019090Phase 2Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of HSK44459 in idiopathic pulmonary fibrosis (IPF), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
HSK44459
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07019090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019090.